Merck’s new melanoma drug which is currently in early phase trials is showing excellent results and promise.
Merck have released data from its Phase Ib trial, from this data they are estimating a 81% survival rate for this drug at the one year mark.
“Simply put, our data make us hopeful that this novel investigational therapy could potentially provide meaningful benefits to patients suffering from this malignant disease,” said Roger M. Perlmutter, head of Merck’s research-and-development arm
